|
|
|
Location: Home -
Products - Reference Compounds&Impurities - Reference Compounds
|
Merimepodib(VX-497)
Catalogue No. : |
C16248 |
Product Name: |
Merimepodib(VX-497) |
Synonym: |
VI-21497;MMPD;VI 21497;VI21497;VX497;VX 497;[[3-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl] carbamic acid (3S)-tetrahydro-3-furanyl ester |
Chemical Name: |
N-[3-[3-[3-Methoxy-4-(5-oxazolyl)phenyl]ureido]benzyl]carbamic acid tetrahydrofuran-3(S)-yl ester;(S)-N-3-[3-(3-methoxy-4-oxazol-5-yl-phenyl)-ureido]-benzyl-carbamic acid tetrahydrofuran-3-yl-ester;(S)-Tetrahydrofuran-3-yl- N-(3-{3-[3-methoxy-4-(oxazol-5-yl) phenyl]ureido;(S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate |
CAS No. : |
198821-22-6 |
Structure : |
|
Molecular Formula: |
C23H24N4O6 |
Molecular Weight: |
452.46 |
Purity: |
>98% |
Usage: |
Merimepodib, also known as VX-497, is orally bioavailable IMPDH inhibitor, which inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM. |
|
Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|